Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary Objective:
To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on Day
14, of administration of Arsucam® as a single daily intake versus two daily intakes.
Secondary Objective:
To compare the clinical safety of the two treatment regimens.